<DOC>
	<DOCNO>NCT01915784</DOCNO>
	<brief_summary>Preference study : Genuair® ( Pressair™ ) v Breezhaler® ( Neohaler™ ) inhalers patient COPD</brief_summary>
	<brief_title>Preference , Satisfaction Ease Use Genuair® ( Pressair™ ) Breezhaler® ( Neohaler™ ) Inhalers Patients With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Adult male female patient age ≥40 year stable moderatetosevere COPD accord GOLD Guidelines classification ( grade II III ) : force expiratory volume 1 second ( measure 10 15 minute postinhalation 400 μg salbutamol ) 30 % ≤FEV1 &lt; 80 % predict normal value Patients naïve study inhaler device , Genuair® Breezhaler® , least 2 year Agreement participate voluntarily sign informed consent form Patients clinically significant uncontrolled chronic disease , particularly body malformation diseases affect coordination and/or motor system Patients unable read product package instruction answer patient report questionnaire ( PASAPQ ) Patients serious uncontrolled mental health problem Patients currently participate randomise clinical study Patients COPD exacerbation within 6 week Visit 1 patient hospitalise COPD exacerbation within 3 month prior Visit 1 Patients condition , investigator 's opinion , might indicate patient inappropriate study Patient likely uncooperative</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>